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the 31st Congress of the European Society of
ardiology was held in Barcelona, Spain, from
ugust 29, 2009, to September 2, 2009, revealing
everal breaking trials in the field of interventional
ardiology. Three years after the World Congress
f Cardiology ignited controversy in the same city
egarding the risk of stent thrombosis with drug-
luting stents (DES), ESC Congress 2009 appro-
riately began their annual session with a review of
ollow-up registry and trial data on stent throm-
osis risk with DES.
CAAR
lthough the initial data from the SCAAR (Swed-
sh Coronary Angiography and Angioplasty Reg-
stry) presented during the 2006 U.S. Food and
rug Administration hearing on the concerns of
ES indicated that combined rates of death and
yocardial infarction (MI) 6 months after percu-
aneous coronary intervention (PCI) were signifi-
antly higher among DES compared with bare-
etal stent (BMS)-treated patients (1), new
CAAR data presented on almost 61,000 patients
reated with stents from 2003 to 2006 showed that
he rates beyond the 1-year mark have been no
ifferent between the 2 arms (2). This further
mphasized the need for dual antiplatelet therapy
ntil complete vascular endothelialization has oc-
urred or for at least 1 year. While there was
eneral acknowledgment of the flaws of registry
ata, there was consensus that the outpouring of
urther data since 2006 have been reassuring for
he continued use of DES. However, the safety
nd efficacy can be variable based on the type of
ES stent used as previously elucidated by various
rials, most recently the ZEST (Zotarolimus-
luting Stent Versus Sirolimus-Eluting Stent and
aclitaxel-Eluting Stent for Coronary Lesions)
rom the *Division of Cardiovascular Medicine, Deborah Heart and
ung Center, Browns Mills, New Jersey; and the †Cardiovascularc
esearch Foundation, Columbia University Medical Center, New York,
ew York.rial presented at the American College of Cardi-
logy Scientific Session 2009 (3).
SAR-TEST-4
n the emerging field of bioabsorbable DES, re-
ults from the ISAR-TEST-4 (Intracoronary
tenting and Angiographic Results: Test Efficacy
f 3 Limus-Eluting Stents) study found a novel
irolimus-eluting stent with a biodegradable poly-
er to be equally as effective as Cypher (Cordis,
iami Lakes, Florida) and Xience (Abbott, Ab-
ott Park, Illinois) stents with their standard per-
anent polymers. The trial of 2,603 patients ran-
omized patients to Cypher, Xience, or a stainless
teel stent coated with a biodegradable polymer
oaded with sirolimus and coated with a bio-
ompatible shellac resin (4). At 1 year, the
iodegradable polymer stent was noninferior to
he combined Cypher/Xience group for the pri-
ary end point of a composite of death, MI, or
arget lesion revascularization (TLR) without any
tatistically significant differences in stent throm-
osis or restenosis.
YNTAX
n the debate between coronary artery bypass
rafting (CABG) versus percutaneous coronary
ntervention (PCI) for complex coronary disease,
he 2-year follow up from the SYNTAX (Synergy
etween PCI with Taxus and Cardiac Surgery)
rial reported continued divergence from the initial
-year data: The 1,800-patient trial found that
ajor adverse cardiac and cerebrovascular events
MACCE) after 1 year occurred significantly more
ften among PCI-treated than among CABG-
reated patients driven by repeat revascularization
n the PCI group (5). Although the composite
afety end point of death/cerebrovascular accident
CVA)/MI rates were almost identical in both
roups, the CVA rate was significantly higher in
he CABG group. At 2 years, MACCE rates
ontinued to be significantly different favoring the
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1161ABG arm, again driven by the repeat revascularization
ate in the PCI arm (6). The higher rate of CVA seen in the
ABG group after the first year did not increase in the
econd year. Furthermore, the trend towards higher MI
oted in the PCI arm at 1 year became statistically signif-
cant at 2 years. Although various reasons for this difference
ave been offered, further data regarding the types of
esultant MI have not been reported.
RACE
espite equivocal results for PCI in complex coronary disease
rom the SYNTAX trial, new data from the GRACE (Global
egistry of Acute Coronary Events) shows that PCI is an
cceptable revascularization strategy in patients with unpro-
ected left main coronary artery disease (LMCAD) presenting
ith acute coronary syndrome (ACS). Although unprotected
MCAD in ACS is a rare entity, it is associated with high
ortality and is primarily treated with PCI rather than being
eferred for CABG or medical therapy which confers greater
isk. The results of 1,799 patients with ACS and LMCAD,
epresenting 4% of patients included in GRACE between
000 and 2007, showed that PCI was associated with a 55%
eduction in the risk of death compared with medical therapy
espite being performed in higher-risk patients that were
eemed poor candidates for surgery (7). Although CABG
rocedures were also associated with a reduction in the risk of
eath, they had higher rates of stroke at 6 months in compar-
son to medical therapy or PCI.
TTEMPT
he results of the ATTEMPT (Pooled Analysis of Trials
n Thrombectomy in Acute MI based on Individual Patient
ata) reaffirmed the benefit of thrombectomy during PCI
or ST-segment elevation myocardial infarction (STEMI).
he grouped results of 11 randomized trials on 2,686
atients with a median follow-up of 365 days found that
andomization to thrombectomy was associated with signif-
cantly lower all-cause mortality and MACE rates (8).
urther subanalysis revealed that the survival benefit was
imited to patients that underwent manual thrombectomy as
pposed to mechanical thrombectomy.
RIANA
he Spanish TRIANA (Tratamiento del Infarto Agudo de
iocardio en Ancianos) trial that compared PCI with
hrombolysis in elderly patients 75 years of age and older
ith acute MI found that primary angioplasty was better in
educing the need for future revascularization with a non-
ignificant trend in favor of reducing death and MI (9). The
rial randomized patients with STEMI of 6 h or less in
uration to thrombolysis with tenecteplase and unfraction-ted heparin or to primary angioplasty. Patients receiving
hrombolysis fared worse in all primary end point compo-
ents: death, reinfarction, and disabling stroke. However,
he trial was underpowered enrolling only 266 patients of
he 570 that were initially planned, due to reluctance on the
art of clinicians to refer for randomization out of concerns
or bleeding from thrombolysis.
LATO
he PLATO (Platelet Inhibition and Patient Outcomes)
tudy compared the treatment of patients with ACS with
he investigational oral antiplatelet agent ticagrelor against
lopidogrel. Patients (n 18,624) admitted with ACS in 43
ountries were randomized to receive either drug with a
oading dose and maintenance in addition to aspirin (10).
he primary end point—a composite of death, MI, or
VA—was significantly lower in the ticagrelor group com-
ared with the clopidogrel group. Moreover, there were no
ignificant differences in the rates of major bleeding between
oth agents. Further results on the PCI cohort to be
resented at a later meeting.
URRENT OASIS-7
hile PLATO announced the superiority of ticagrelor, the
URRENT OASIS-7 (Clopidogrel Optimal Loading
ose Usage to Reduce Recurrent Events Optimal Anti-
latelet Strategy for Investigators-7) trial showed that dou-
ling the doses of clopidogrel for the first week in ACS
atients undergoing planned PCI reduced stent thrombosis
nd cardiovascular events. The trial of 17,232 patients who
nderwent PCI, demonstrated a significant reduction of
ardiovascular death, MI, and CVA in the double-dose arm
hat was driven primarily by the reduction in MI (11). In
ddition, there was no significant difference in major bleed-
ng despite doubling the dosage of clopidogrel.
UMMARY
he 2009 Congress of the ESC was the venue for new data on
reaking clinical trials and established follow-up on some
revious trials in interventional cardiology. Complete coverage
f ESC Congress 2009 can be accessed at the American
ollege of Cardiology’s Cardiosource website (12).
eprint requests and correspondence: Dr. Jon C. George,
ivision of Cardiovascular Medicine, Deborah Heart and Lung
enter, 200 Trenton Road, Browns Mills, New Jersey 08015.
-mail: jcgeorgemd@hotmail.com.
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